Home Cart Sign in  
Chemical Structure| 4291-60-5 Chemical Structure| 4291-60-5

Structure of Tilianin
CAS No.: 4291-60-5

Chemical Structure| 4291-60-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tilianin is a flavonoid glycoside of Dragocephalum moldavicum L. .

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tilianin

CAS No. :4291-60-5
Formula : C22H22O10
M.W : 446.40
SMILES Code : O=C1C=2C(OC(=C1)C3=CC=C(OC)C=C3)=CC(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)=CC2O
MDL No. :MFCD00238695
InChI Key :NLZCOTZRUWYPTP-MIUGBVLSSA-N
Pubchem ID :5321954

Safety of Tilianin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
H9c2 cardiomyocytes 10, 30, 50 μg/mL 2 hours OGD followed by 4 hours reoxygenation To evaluate the protective effects of Tilianin against OGD/R-induced injury in H9c2 cells. Results showed Tilianin significantly enhanced cell viability, inhibited TLR4/NF-κB pathway and NLRP3 inflammasome activation, and reduced ASC speck formation and inflammatory cytokine release. Front Pharmacol. 2024 Oct 23;15:1423053
SH-SY5Y cells 10 mM and 30 mM 24 hours Tilianin increased the downregulated miR-193b-3p and miR-152-3p levels in OGD-injured SH-SY5Y cells. Front Immunol. 2023 Apr 19;14:1118808
FaDu cells 10, 30, 100 µM 24 hours (apoptosis assay), 48 hours (qPCR, Western blot, ELISA analyses), 14 days (plate clone formation assay) Tilianin inhibited FaDu cell proliferation and induced apoptosis in a dose-dependent manner. It upregulated pro-apoptotic factors Bax and Bad, downregulated anti-apoptotic factors Bcl-2 and Bcl-xL, activated caspase-3 and PARP, and stimulated cytochrome c release, thereby inducing apoptosis via the mitochondrion-dependent intrinsic apoptotic pathway. Front Pharmacol. 2020 Mar 4;11:205

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague-Dawley rats Myocardial ischemia/reperfusion injury model (LAD ligation/release) Intraperitoneal injection 3, 10, 30 mg/kg Single dose at reperfusion onset, lasting 24 h To investigate the cardioprotective mechanisms of Tilianin in MIRI. Results demonstrated Tilianin improved cardiac function (reduced LVESD, increased LVEF/LVFS), decreased infarct size and apoptosis, and suppressed TLR4/NF-κB/NLRP3 pathway and inflammatory cytokines (IL-1β, IL-18) release. Front Pharmacol. 2024 Oct 23;15:1423053
Sprague-Dawley rats 2VO vascular dementia model Oral 40 mg/kg Once daily for four weeks Tilianin ameliorated cognitive deficits, neurodegeneration, and microglial and astrocytic activation in rats with 2VO. Front Immunol. 2023 Apr 19;14:1118808
C57BL/6 mice Ischemia/reperfusion-induced acute kidney injury model Intragastric administration 5 mg/kg, 10 mg/kg, 15 mg/kg Once daily for 7 days Tilianin reduces apoptosis via the ERK/EGR1/BCL2L1 pathway in ischemia/reperfusion-induced acute kidney injury mice. Front Pharmacol. 2022 Jun 3;13:862584

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.24mL

0.45mL

0.22mL

11.20mL

2.24mL

1.12mL

22.40mL

4.48mL

2.24mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories